<DOC>
	<DOCNO>NCT01816815</DOCNO>
	<brief_summary>Effects BAY1002670 bleed pattern : non-bleeding rate ; endometrium ; ovarian function ; return menstrual bleeding treatment ; safety tolerability ; PK/PD ( pharmacokinetic/pharmacodynamic ) relationship</brief_summary>
	<brief_title>Study Healthy Tubal Ligated Women Evaluate Pharmacodynamics , Safety Pharmacokinetics BAY1002670</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<criteria>Healthy female subject Sterilized tubal ligation Age 1845 year Body mass index ( BMI ) screening : ≥ 18 ≤ 32 kg/m² At least 3 consecutive regular menstrual cycle cycle length 24 35 day first screen examination accord subject 's history Absence clinically relevant abnormal finding pretreatment endometrial biopsy Regular use medicine ( incl . anabolics ) Incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Amenorrhea 3 month within last 6 month first screen examination Lacking suitability frequent transvaginal ultrasonography ( TVU ) examination Clinically relevant finding ( e.g . blood pressure , electrocardiogram [ ECG ] , physical gynecological examination , laboratory examination )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>PK/PD</keyword>
	<keyword>BAY1002670</keyword>
</DOC>